Home/Filings/4/0000899243-18-018317
4//SEC Filing

DAVIS JOHN C. JR 4

Accession 0000899243-18-018317

CIK 0001690585other

Filed

Jun 26, 8:00 PM ET

Accepted

Jun 27, 4:24 PM ET

Size

7.0 KB

Accession

0000899243-18-018317

Insider Transaction Report

Form 4
Period: 2018-06-25
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
  • Conversion

    Common Stock

    2018-06-25+8,3048,304 total
  • Conversion

    Series C Preferred Stock

    2018-06-2521,4590 total
    Common Stock (8,304 underlying)
Footnotes (1)
  • [F1]The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date.

Issuer

Magenta Therapeutics, Inc.

CIK 0001690585

Entity typeother

Related Parties

1
  • filerCIK 0001741287

Filing Metadata

Form type
4
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 4:24 PM ET
Size
7.0 KB